DDInter204 DDInter1747
Bicalutamide is an oral non-steroidal anti-androgen for prostate cancer. It is comprised of a racemic mixture that is a 50:50 composition of the (R)-bicalutamide and (S)-bicalutamide enantionmers. Bicalutamide binds to the androgen receptor.
Tasimelteon is a selective dual melatonin receptor agonist indicated for the treatment of Non-24-Hour Sleep-Wake Disorder (N24HSWD). Occurring commonly in blind individuals without light perception, this condition is often characterized by periods of night-time insomnia and day-time sleepiness. In blind individuals, a lack of light stimulation causes an extension of the 24-hour circadian cycle and can lead to progressively delayed sleep onset. By activating melatonin receptors MT1 and MT2 in the suprachiasmatic nucleus of the brain, tasimelteon has been shown to improve sleep by resynchronizing the circadian rhythm through its "non-photic" mechanism. Tasimelteon is currently the only drug available for the treatment of N24HSWD and was granted orphan drug status by the FDA in 2010.
Bicalutamide {u} (Compound) resembles {v} (Compound) Enzalutamide
Bicalutamide {u} (Compound) treats {v} (Disease) prostate cancer
Bicalutamide {u} (Compound) binds {v} (Gene) AR
Bicalutamide {u} (Compound) upregulates {v} (Gene) USP6NL
Bicalutamide {u} (Compound) is included by {v} (Pharmacologic Class) Androgen Receptor Antagonists
Bicalutamide {u} (Compound) downregulates {v} (Gene) TUBB6
Bicalutamide {u} (Compound) causes {v} (Side Effect) Melaena
Bicalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Bicalutamide {u} may cause a minor interaction that can limit clinical effects when taken with {v} Naloxegol
Bicalutamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilpivirine
Bicalutamide (Compound) resembles Enzalutamide (Compound)
Bicalutamide (Compound) treats prostate cancer (Disease)
Bicalutamide (Compound) binds AR (Gene)
Bicalutamide (Compound) upregulates USP6NL (Gene)
Bicalutamide (Compound) is included by Androgen Receptor Antagonists (Pharmacologic Class)
Bicalutamide (Compound) downregulates TUBB6 (Gene)
Bicalutamide (Compound) causes Melaena (Side Effect)
Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Bicalutamide may cause a minor interaction that can limit clinical effects when taken with Naloxegol
Bicalutamide may cause a moderate interaction that could exacerbate diseases when taken with Rilpivirine